Articles for author: The whipping post

The whipping post

Is Wall Street Bullish or Bearish on Cintas Stock?

Cincinnati, Ohio-based Cintas Corporation (CTAS) provides corporate identity uniforms and related business services primarily in the United States, Canada, and Latin America. With a market cap of $89.4 billion, Cintas operates through Uniform Rental and Facility Services, First Aid and Safety Services, and Other segments. Cintas has substantially outperformed the broader market over the past ...

The whipping post

A Black Friday Deal for Your Portfolio

Hello, Reader. 40% off select models. Up to 70% off clearance. Limit one coupon code per customer. We’ve been bombarded with Black Friday deals for weeks now. What used to be a one-day-only, in-store event has turned into a month-long celebration of “the best deals of the year.” So, in the spirit of the week, ...

The whipping post

Jeff Yass vs. Ken Griffin: 1 Billionaire's Firm Is Selling Nvidia Stock While the Other's Has Nearly Tripled Its Stake

Jeff Yass and Ken Griffin are in a league of their own. Yass is the co-founder and managing director at the global quantitative trading firm Susquehanna International Group, while Griffin is CEO of the massive “pod shop” hedge fund Citadel. Both billionaires have built financial empires and are quite skilled at their trade. That’s why ...

The whipping post

Flux Power Receives Non-Compliance Letter from Nasdaq

Flux Power Holdings, Inc. FLUX, a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, today announced that on November 20, 2024, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with requirements of ...

The whipping post

Two Smaller Companies Worthy of Your "Attention"

Elite Pharmaceuticals Inc. (ELTP) fits nicely into the nexus of the increasing diagnoses of ADHD and the patent expiration of the branded drug Vyanse in 2023 for its treatment. Elite Pharmaceuticals Inc. recently received FDA approval for its generic version of Vyanse and expects to launch the product in early 2025.  Image Source: Zacks Investment ...

The whipping post

Is Market Optimism Reaching Potentially Dangerous Levels?

Optimism is climbing, but are valuations too high? Key risk indicators signal caution as sentiment soars. Investors face a tough balancing act in today’s market. The market has come a long way since the October 2022 low, with optimism creeping back in. But with this renewed confidence comes a need to tread carefully. As investor ...

The whipping post

ResMed Stock: Is Wall Street Bullish or Bearish?

With a market cap of $35.8 billion, ResMed Inc. (RMD) is a global leader in the design, manufacturing, and distribution of medical devices and cloud-based software for the treatment of sleep-disordered breathing (SDB) and other respiratory conditions. It operates through two segments: Sleep and Respiratory Care, and Software-as-a-Service, offering innovative products and solutions for respiratory health ...